SCHEMBL5937

SCHEMBL5937

Brc1ccccc1-n1cnc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.56
HCAR1 Q9BXC0 1/20 0.54
POLB P06746 1/20 0.51
FGFR1 P11362 3/20 0.50
ALDH1A1 P00352 1/20 0.46
ROCK1 Q13464 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29898298 1.00 HTT (0.56) HTTHCAR1POLBFGFR1ALDH1A1
SCHEMBL3417306 0.86 HTT (0.73) HTTPOLBFGFR1ALDH1A1ROCK1
SCHEMBL24179153 0.85 FGFR1 (0.51) HTTHCAR1POLBFGFR1ALDH1A1
SCHEMBL22188457 0.81 HTT (0.56) HTTPOLBFGFR1ROCK1MKNK1
SCHEMBL23266636 0.81 HTT (0.60) HTTPOLBFGFR1ALDH1A1ROCK1
SCHEMBL31072244 0.80 HCAR1 (0.53) HTTHCAR1POLBFGFR1
SCHEMBL23840256 0.79 HTT (0.58) HTTPOLBFGFR1ALDH1A1ROCK1
SCHEMBL56852 0.79 FGFR1 (0.61) HTTPOLBFGFR1ALDH1A1
SCHEMBL23840275 0.78 FGFR1 (0.58) HTTPOLBFGFR1ALDH1A1ROCK1
SCHEMBL7211112 0.78 HTT (0.56) HTTHCAR1POLBFGFR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1097618-B1 POST-TREATMENT FOR COPPER ON PRINTED CIRCUIT BOARDS FRYS METALS INC DBA ALPHA METALS INC (US) 2003-03-26 EP claimed
US-12052915-B2 Organic electroluminescence device and polycyclic compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-30 US disclosed
US-11696492-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-07-04 US disclosed
US-11424420-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2022-08-23 US disclosed
US-20210119138-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2021-04-22 US disclosed
CN-112670421-A Organic electroluminescent device 三星显示有限公司 2021-04-16 CN disclosed
US-20200220090-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2020-07-09 US disclosed
US-20190074455-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-03-07 US disclosed
US-9865952-B2 Plug contact with organic coating and printed circuit board arrangement CONTINENTAL AUTOMOTIVE GMBH (DE) 2018-01-09 US disclosed
US-20170179628-A1 PLUG CONTACT WITH ORGANIC COATING AND PRINTED CIRCUIT BOARD ARRANGEMENT CONTINENTAL AUTOMOTIVE GMBH (DE) 2017-06-22 US disclosed
EP-2991644-A2 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY University of Maryland, Baltimore (US) 2016-03-09 EP disclosed
EP-2935240-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-10-28 EP disclosed
WO-2014165815-A2 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-10-09 WO disclosed
WO-2014100695-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-06-26 WO disclosed
EP-2493310-A1 BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline LLC (US) 2012-09-05 EP disclosed
US-20120208827-A1 BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2012-08-16 US disclosed
WO-2011056635-A1 BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
US-20110046105-A1 Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
EP-2242746-A1 HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF Sanofi-Aventis (FR) 2010-10-27 EP disclosed
WO-2009098000-A1 HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208827-A1 BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 HTT 4048/4885HCAR1 857/4885POLB 1739/4885
US-12052915-B2 Organic electroluminescence device and polycyclic compound for organic electroluminescence device BMI1, L1CAM, EML4 HTT 4388/4885HCAR1 4843/4885POLB 1851/4885
US-20110046105-A1 Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof GIPR, DDC, PGC HTT 1571/4885HCAR1 1633/4885POLB 2947/4885
US-20200220090-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, OCIAD2, ODC1 HTT 2667/4885HCAR1 4689/4885POLB 733/4885
US-20190074455-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES L1CAM, SOD1, OR10J3 HTT 3268/4885HCAR1 3993/4885POLB 1781/4885
US-11696492-B2 Organic electroluminescent materials and devices OCIAD1, OCIAD2, ODC1 HTT 2667/4885HCAR1 4689/4885POLB 733/4885
US-11424420-B2 Organic electroluminescent materials and devices L1CAM, SOD1, OR10J3 HTT 3268/4885HCAR1 3993/4885POLB 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.